Group 1 - The company, 来凯医药-B (02105), announced a proposed placement of 36 million shares, representing approximately 8.1% of the enlarged issued share capital post-completion [1] - The placement price is set at HKD 16.30 per share, which reflects a discount of about 9.5% compared to the closing price of HKD 18.01 on September 9 [1] - If all 36 million shares are fully subscribed, the total proceeds from the placement will amount to HKD 586.8 million, with the estimated net proceeds being HKD 577.5 million [1] Group 2 - Approximately 90% of the net proceeds from the placement will be allocated to research and development of clinical and preclinical pipeline projects [1] - The remaining 10% of the net proceeds will be used for general and corporate purposes [1]
来凯医药-B(02105)拟折让约9.5%配售3600万股 净筹约5.775亿港元